Related Experiment Video

Updated: Jun 10, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Angiogenesis and chronic kidney disease

Yohei Maeshima1, Hirofumi Makino

  • 1Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. ymaeshim@md.okayama-u.ac.jp.

Fibrogenesis & Tissue Repair
|August 7, 2010
PubMed

Insights

Chronic kidney disease (CKD) progression involves angiogenesis. Modulating these factors offers potential therapies for CKD and end-stage renal disease (ESRD), requiring further research for optimal treatment strategies.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Angiogenesis Research

Background:

  • Increasing global prevalence of end-stage renal disease (ESRD) necessitates understanding chronic kidney disease (CKD) progression.
  • CKD is a significant risk factor for ESRD and complicates cardiovascular disease (CVD).
  • Emerging research highlights the role of angiogenesis-related factors in CKD development and progression.

Purpose of the Study:

  • To review the involvement of angiogenesis-related factors in CKD.
  • To explore the therapeutic potential of modulating these factors for CKD and related conditions.
  • To identify future research directions for pro- or anti-angiogenic therapies in CKD.

Main Methods:

  • Literature review of studies on angiogenesis factors in kidney disease.
  • Analysis of the roles of vascular endothelial growth factor (VEGF)-A and Angiopoietin (Ang)-1 in kidney development and disease.
  • Examination of therapeutic effects of angiogenesis inhibitors in experimental models.

Main Results:

  • VEGF-A is crucial for kidney development, glomerular structure, and repair, and implicated in diabetic nephropathy.
  • Ang-1 promotes blood vessel maturation and shows therapeutic potential in diabetic nephropathy.
  • Various angiogenesis inhibitors (e.g., angiostatin, endostatin) have demonstrated therapeutic effects in experimental diabetic nephropathy models.

Conclusions:

  • Angiogenesis-related factors play a significant role in CKD progression.
  • Targeting these factors presents potential therapeutic avenues for CKD.
  • Further research is needed to determine optimal therapeutic timing and develop targeted drug delivery systems for CKD patients.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...